Calidi Biotherapeutics, Inc. (CLDI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Calidi Biotherapeutics, Inc. (CLDI) closed at USD 0.87 on 2026-10-14, a change of -96.4 % over the past year, with a market capitalization of USD 3.2M.

Calidi Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Calidi Biotherapeutics, Inc. key figures

Previous close

USD 0.87 (2026-10-14)

1-year change

-96.4 %

Market cap

USD 3.2M

Enterprise value

USD 127,655

P/E ratio (trailing)

-0.03

P/E ratio (forward)

-0.97

EPS (trailing)

-35.42

EPS (forward)

-0.90

PEG ratio

n/a

Price to book

0.58

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.12

Employees

29

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Calidi Biotherapeutics, Inc. and compare it with other stocks.